Edwards Lifesciences (EW) Tops Q1 EPS by 4c, Offers Guidance

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.64, $0.04 better than the analyst estimate of $0.60. Revenue for the quarter came in at $1.41 billion versus the consensus estimate of $1.4 billion.

GUIDANCE:

Edwards Lifesciences sees FY2025 EPS of $2.40-$2.50, versus the consensus of $2.45.

Edwards Lifesciences sees Q2 2025 EPS of $0.59-$0.65, versus the consensus of $0.62. Edwards Lifesciences sees Q2 2025 revenue of $1.45-1.53 billion, versus the consensus of $1.47 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• MakeMyTrip (MMYT) PT Raised to $65 at JPMorgan
• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half